Sunday, April 29, 2007

Biotechnology News

The Cost of Just One Age-Related Condition The solutions proposed in the article are, as ever, second-rate, given that we're in the midst of a biotechnology revolution. The real solution to age-related disease is to push hard for cures, preventions, and real anti-aging research ...

Judge mulls making alfalfa ban permanent (Reuters) By Yahoo! News: Biotechnology News Reuters - A US judge questioned whether he should lift a ban on the sale and planting of Monsanto Co.'s genetically modified alfalfa without a government study of the crop's potential impact.

Ben & Jerry's Embraces GM Ice Cream Protein?
According to an article published in, Unilever, the parent company of Ben & Jerry’s, one of the most visible anti-biotechnology ice cream makers in the United States, has moved closer to gaining approval in Europe to ...

Biotech News
AZhttp, Inc.


Biotech News

Zambia continues to be cautious in dealing with genetically ...
People's Daily Online - Beijing,China Speaking during the commissioning of the National Biotechnology Laboratory in Lusaka, the president said the whole world is aware that the implications of ...

Firms join on biotech
Capital Press (subscription) - Salem,OR,USA BASF and Monsanto Company recently announced a long-term joint research and development and commercialization collaboration in plant biotechnology that will ...

AZhttp, Inc.

BioHealthRx Medical Jobboard Integrates Cross Posting Software With Major Jobsites

Biotech News
AZhttp, Inc.

Fast Growing Medical Jobboard Integrates Cross Posting Software With Major Jobsites
BioHealthRx provides a single resource to post medical jobs to Monster, Careerbuilder, MedHunters, Absolutely Healthcare among others

Date Released: 04/28/2007
Louisville, KY May 3, 2007 BioHealthRx, a recently launched unique medical jobboard has announced that it has now added cross posting software to allow employers and recruiters in the Biotechnology, Healthcare, and Pharmaceutical industries to post jobs not only to BioHealthRx jobboard, but also to the major players such as Monster, Careerbuilder, MedHunters, Absolutely Healthcare and HotJobs among others. The recently launched site also acts as a complete resource for professionals in these industries.
Employers and recruiting firms will have the option to not only cross post jobs, but also will be able to generate reports that will allow them to view applicant views, expiring jobs, where their jobs are posted, and what applicants have applied. This process will efficiently streamline the time consuming tasks of manually posting jobs as well as being able to keep track of their job postings without the need to continuously check each individual jobboard. Jeri Lyskowinski, CEO and President, of BioHealthRx states that “employers are busy enough and do not need to add additional work to their already jam packed schedules.” Employers will simply sign up for the cross posting feature and as long as they have an account with any of the jobboards they will be able to post their jobs to any of their own choosing and then be billed by the respective jobboards.

BioHealthRx goes beyond the benefits of a typical jobboard by providing a single resource for professionals who are continually and increasingly barraged with information. BioHealthRx features more than 170 medical job categories and is host to biotechnology jobs, healthcare jobs, pharmaceutical jobs, medical journals, medical articles, medical books, medical news, drug database, CME and CE courses and medical forums.

The US Bureau of Labor Statistics has stated that by the year 2014, there will be more than 3.6 million healthcare positions available. That is a 27.3-percent higher job growth rate than the expected 14-percent rate of all other industries combined. “It’s a big number and we need to be prepared by providing useful services for not only the clinical and research employees, but also the employers to help keep high retention rates and lower turnover.” Lyskowinski adds. “The medical industry is by far the premier industry in which to work. Advances in technology and research are announced daily by some of the brightest minds in the world.”

BioHealthRx selected HRsmart to host the career site because of the enhanced functionality they were able to provide such as applicant tracking technology. The embedded and streamlined ATS will allow recruiters and hiring managers to manage their applicant and candidate work flow leading to cost-savings for more accurate and efficient hires. Employers are able to upload a video to let jobseekers know why they should work for them, in addition to job posting/template creation, screening questionnaires, resume searching, match jobseekers to skills assessments, mini applicant tracking system, and much more.

A wide range of companies is targeted for the web site, including pharmaceuticals, medical facilities, and biotechnology companies, as well as those which participate in drug research and development, CRO—companies that manufacture coatings for pills—and medical supply houses.

About BioHealthRx

Founded by CEO and President Jeri Lyskowinski, BioHealthRx is a career site and resource center for the biotechnology, healthcare and pharmaceutical industries. It was founded with a desire to provide a single-resource for the busy medical professional.

About HRsmart Founded in 1994, HRsmart provides a fully hosted, network-delivered suite of talent management software solutions including applicant tracking, online recruiting, performance management, learning management, career development, succession planning, employee referral and job distribution.

HRsmart supports a wide range of clients including, but not limited to, the medical, retail, manufacturing, financial, government, hospitality, petrochemical and telecommunications industries.

Many organizations, including Fortune 500 companies, commercial public career boards and recruiting firms, turn to HRsmart for their talent management needs.

HRsmart has operations in the United States, Europe, Canada and Latin America and offers solutions in English, Portuguese, Spanish and French. For more information, please visit

Contact: Jeri Lyskowinski CEO/President BioHealthRx Phone: 866-762-5797 jeri(at)

Contact: Lori Morgan Marketing Manager/PR HRsmart Phone: 972-783-3050 lmorgan(at)


About BioHealthRx
BioHealthRx, a leading medical jobs careersite for the biotechnology, healthcare, and pharmaceutical industries. Featuring not only top medical jobs, but also the freshest resumes, salary wizard, books, medical journals, career center and much more. Our medical libraries are unique as each individual library features medical news, medical meetings and conferences, drug database, and other content that provides you up-to-date information. Our website features jobs from the US, Canada, UK, Europe and many other countries
We have many exciting and unique things that will put us on the map in 2007. Many things have never been done by jobboards, so stay tuned for an exciting year!

Submitted by BioHealthRx

Tuesday, April 24, 2007

Biotechnology News

NE Ohio biotech investment soars
Crain's Cleveland Business - Cleveland,OH,USA The money garnered by Northeast Ohio biotech companies was nearly four times the $22 million attracted throughout all of Ohio during the first quarter of ...

Tuesday's Top Biotech & Medical Stocks
by HS Ayoub BioHealth Biotechnology PHARMOS CORP [PARS] +19.23% NUTRITION 21 INC [NXXI] +15.06% ADVENTRX PHARMACTL [ANX] +14.46% AURIGA LABORATORIES [ARGA.OB] +11.89% HALOZYME THERAPEUTIC [HTI] +11.40% Diagnostic. ...

Biotech Attracts More VC Funding: Study
Venture capitalists are getting more excited about biotech now that big pharma is on a shopping spree. The MoneyTree report to be released today finds that VC outlays in this year's first quarter rose 13.5 percent from $6.2 billion ...

Mold By-Product Chaetocin May Treat Myeloma According to a study presented at the American Association for Cancer Research annual meeting, chaetocin, a by-product of a common wood mold, may hold promise as a new therapeutic against myeloma, an incurable bone marrow cancer. Dr. ...

Biotech News
AZhttp, Inc.

Biotech News

Biotech News

Biotech Seeks Partners, Investments at Conference Cabarrus Business & Lifestyles Magazine - Concord,NC,USA According to officials, Vice President of Business Development Clyde Higgs will attend the conference, focusing on recruitment biotech companies to the ...

AstraZeneca buys US biotech company for US$15.6b The Brunei Times - Bandar,Brunei,Brunei Darussalam ANGLO-SWEDISH pharmaceuticals giant AstraZeneca yesterday said it has agreed to buy American biotechnology company MedImmune for US$15.6 billion
(€11.5 ...

Bodisen Biotech stock to be removed from Amex on May 4 - stock market Forbes - NY,USA NEW YORK (Thomson Financial) - The American Stock Exchange (Amex) said it has made a final decision to remove shares of Bodisen Biotech Inc, which is also ...

Blame it on biotech mosquito bites
Western Farm Press - USA
Maybe that explains why your brain turns to mush when writing about biotech topics. Now you'll have to use genetically-modified insect repellent to get back ...

Feuerstein's Biotech Bonus Mailbag - USA
Writing Biotech Mailbag every Saturday has been a great experience all around. My only regret is that I don't get a chance to provide as many company ...

Biotech helps propel state investment totals Seattle Post Intelligencer - Seattle,WA,USA As I point out in today's story, the $134 million figure is just shy of the total raised by all biotech companies in the state last year. ...

AZhttp, Inc.

Biotech News

Biotech News

Web site focuses on biotech jobs
San Diego Union Tribune - San Diego,CA,USA The two groups host an annual biotech job fair in San Diego. “We hope for this initiative to serve as an exemplary work force development model for other ...

Biotech sector reaps big bucks
San Francisco Chronicle - San Francisco,CA,USA "It was the strongest quarter ever for biotech and medical devices since we started keeping numbers 10 years ago," said Mark Heesen, president of the ...

BIO to Unveil Innovative Polls Comparing Views of Top-Level ... - New Delhi,India
The Biotechnology Industry Organization (BIO) will launch its 2007 BIO International Convention in Boston on May 6 with a special media-only brunch that ...

AZhttp, Inc.

Monday, April 23, 2007

Pathogen Genomics and Bio-defense Research Facility Opens in Flagstaff

Pathogen Genomics and Bio-defense Research Facility Opens in Flagstaff

TGen North Expands Arizona’s Bioscience Corridor


Flagstaff, AZ, April 13, 2007--With bio-terrorism a stark reality in today's world, understanding and combating this threat is essential for the nation's security. Today, the Translational Genomics Research Institute (TGen), Northern Arizona University (NAU) and a host of elected officials celebrated the formal opening of TGen North, the new pathogen genomics and biodefense research facility in Flagstaff. The facility joins the ranks of a number of facilities across the country today whose research centers on the detection and prevention of biological threats. Although operational for the past year, today's event marked the move to TGen North's permanent facility that contains more than 4,500 square feet of state-of-the-art research laboratories and office space.
"Opening the doors of TGen North is a concrete step toward bringing new bioscience jobs and opportunities to the people of northern Arizona and furthers the State's efforts toward building out the bioscience corridor," said Congressman Renzi, whose support was key to planning and launching TGen North. "The unique work done at TGen North is dedicated to improving public health and biosecurity for our nation."

TGen North researchers use the latest in genomic technology to develop smarter and faster diagnostics for infectious diseases, including the use of new analytical tools to create better therapies and new vaccines.

Dr. Bert Weinstein, Former Associate Director of Biology and Biotechnology Research Programs at Lawrence Livermore National Laboratory, said, "This new TGen North facility builds upon a decade of critical biodefense and forensic work by the scientific team in Northern Arizona and will help our country in the battle against terrorists and naturally emerging diseases."

TGen North is comprised of three research centers: 1) Center for Public Health and Clinical Pathogens, 2) Center for Dangerous Pathogens, and 3) Center for Pathogen Bioinformatics. "The advances being developed at TGen North will help doctors-from our local hospitals to the battlefield-to not only quickly identify dangerous pathogens, but to better characterize the nature of those pathogens by identifying genetic markers that cause antibiotic resistance or increased virulence," said nationally recognized biosafety expert Dr. Paul Keim, Director of TGen's Pathogen Genomics Division and Professor of Biology and Cowden Endowed Chair in Microbiology at NAU.

TGen North's initial research activities are focused on common infectious diseases like influenza and valley fever, important hospital infections like drug-resistant staphylococcus, and a number of bioterrorism agents, including tularemia and plague.

"TGen North represents our ongoing commitment to all of Arizona," said Dr. Jeffrey Trent, President and Scientific Director of TGen. "The biodefense and public health research we are doing at TGen North is a direct expansion of our mission to provide earlier diagnostics, in this case to dangerous pathogens."

TGen North is a collaborative effort between TGen and NAU. As such, several joint and adjunct TGen-NAU faculty members staff the facility. Furthermore, TGen North has access to the advanced Biosafety Level 3 facilities on the NAU campus as well as the comprehensive genomic research capabilities of TGen Headquarters in Phoenix.

"The partnership continues to strengthen the ties between TGen and NAU. It is my hope that TGen North will further establish Northern Arizona as a premier site for pathogen research," said Dr. John Haeger, President of NAU.

David Engelthaler, the former Arizona State Epidemiologist, will provide the day-to-day management of TGen North. In addition to NAU, TGen North has many local national and international research partners, including universities, biotech companies, security agencies, health care providers, and public health departments.

"To go from a virtual lab to a bricks and mortar facility in just under a year speaks to the remarkable pace at which the bioscience economy is taking root in Flagstaff and all across Arizona," said Flagstaff Mayor Joe Donaldson.

TGen North is funded by multiple federal agencies that support medical diagnostics, forensic analyses and biodefense-related work including the National Institutes of Health, the Department of Defense, Department of Justice, the Department of Homeland Security and others.

# # #

About TGen
The Translational Genomics Research Institute (TGen) is a non-profit 501(c)(3) organization focused on developing earlier diagnostics and smarter treatments. Translational genomics research is a relatively new field employing innovative advances arising from the Human Genome Project and applying them to the development of diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases. TGen's research is based on personalized medicine. The institute plans to accomplish its goals through robust and disease-focused research.

About Northern Arizona University
Northern Arizona University (NAU) has a student population of about 20,000 at its main campus in Flagstaff and at 30 sites across the state. NAU has earned a solid reputation as a university with all the features of a large institution but with a personal touch. NAU carefully balances teaching, scholarship and service with a faculty and staff dedicated to each student's success. While our emphasis is undergraduate education, we offer a wide range of graduate programs and research that extend to such national concerns as forest health and bioterrorism.

Biotech Marketing
Marketing Firms

Viventia Biotech generates novel human anti-cancer antibody, VB1 ...

Biotech News
AZhttp, Inc.

Annual General Meeting of Active Biotech AB

LUND, Sweden, April 20, 2007-The Annual General Meeting (AGM) of Active Biotech AB was held on April 19, 2007.

Board members Sven Andréasson, Mats Arnhög, Professor Klas Kärre, Peter Sjöstrand and Peter Ström were re-elected by the AGM. The AGM also decided to appoint Mats Arnhög as Chairman of the Board.

Magnhild Sandberg-Wollheim was elected as a new member of the Board. She is an associate professor of Neurology and Chief Medical Officer at the neurological clinic at Lund University Hospital. Magnhild Sandberg-Wollheim has forty years' experience of treating patients with multiple sclerosis and her research has largely focused on clinical, immunological and genetic problems of this disease.

Viventia Biotech generates novel human anti-cancer antibody, VB1 ...
Viventia Biotech Inc. announced that it has generated a novel, fully human anti-cancer antibody, VB1-050, and also identified the novel target for the antibody, a mutant form of the protein Glut-8. ...

Cap on Visas for Skilled Foreign Workers Stifling Biotech, Tech San Diego Business Journal - CA,USA “Biotech is an industry that is going to continue

Cap on Visas for Skilled Foreign Workers Stifling Biotech, Tech San Diego Business Journal - CA,USA “Biotech is an industry that is going to continue to boom, and we need a work force that fits the industry needs,” she said. ...

Burgeoning Biotech Sector Demands Investor Attention FINalternatives - New York,NY,USA Chicago-based Kilkenny Capital Management, which manages $200 million in long/short biotech funds, has been investing in this growing marketplace for 12 ...

Biotech News
AZhttp, Inc.

Biotech Company NuGEN Technologies Secures $3 Million American Venture Magazine (press release) - Palo Alto,CA,USA ... Inc., a biotech company that develops and commercializes high-sensitivity nucleic acid amplification and labeling technologies used in gene expression ...

Biotech Roundup: Goldman Short Selling, Biotech Short Interest ... - New York,USA
Biotech short interest (as measured by short interest of companies in the NASDAQ Biotech Index) was up almost 10% in the Feb-March period, ...

Leading Australian Biotech CEOs to Showcase Cutting-Edge Science at New York City Conference

Leading Australian Biotech CEOs to Showcase Cutting-Edge Science at New York City Conference

Dr. Ian Frazer, Developer of the HPV Vaccine, Will Keynote May 3 Event

SYDNEY, Australia -- Apr 20, 2007 - Executives from nine of Australia's top biotechnology firms will present "what's hot" in biotech Down Under on Thursday, May 3, at the second annual Australian Bio-Investment Forum in New York City. Hosted by Australian investment and brokerage firm Emerging Growth Capital (eG Capital), the conference is being held at the offices of Ernst & Young, Five Times Square.

In addition, Dr. Ian Frazer, a key developer of the vaccine to prevent cervical cancer and 2006 Australian of the Year; Dennis Purcell of Aisling Capital, an early, and continuing investor in biotech; and Fred Welz, Senior Investment Commissioner, Invest Australia will address the audience of investment bankers, analysts, seed investors, venture capitalists and pharmaceutical company representatives.

"Australia has the largest biotechnology presence in the Asia-Pacific region, and has attracted more venture capital than any other country in the area--more than A$630 million in 2006, said Mark Fordree, Managing Director, eG Capital. "We are delighted to introduce some of its premier firms to New York's investment and pharma community at our second investor forum here. Each company has been selected for its investment potential based on development track record, product portfolio, growth strategy and corporate structure."

Participating companies include:

-- Biota (ASX: BTA)--A leader in antiviral drug development, discovered zanamir, marketed today by GSK as Relenza(R), for seasonal and pandemic avian flu.

-- Circadian Technologies (ASX: CIR)--A biotech investment company holding a large stake in Avexa (ASX: AVX), which recently announced successful Phase 2b results for its HIV drug, and in Vegenics, a private company targeting tumor blood vessel growth.

-- Cytopia (ASX: CYT) -Creating drugs to treat cancer and cardiovascular disease, Cytopia is collaborating with Novartis to develop a drug using its JAK 3 inhibitors to prevent transplant rejection.

-- EvoGenix Ltd. (ASX: EGX)--Is using its proprietary antibody platforms to develop antibody therapies for bone loss, respiratory infection and cancer. In collaboration with the National Institute of Health (NIH), they are working to develop antibody therapies against a new cancer target.

-- HeartWare (ASX: HTW)--Developing a family of proprietary, miniature circulatory assist devices to treat patients with heart failure, HeartWare's lead device, the HVAD(TM), with a volume of 45 cc, is progressing through an international clinical trial. HVAD is currently the smallest pump and the only full output device implantable within the thoracic cavity.

-- ImpediMed Ltd. (unlisted, public)--Are developing and marketing bio-impedence devices to accurately measure body composition. Applications include the early detection and monitoring of lymphodema, muscle wasting, weight management, drug dosing and monitoring.

-- OptiScan Imaging Ltd. (ASX: OIL)--With Pentax, has developed a confocal endomicroscope that displays sharp focus and high resolution images that provide such accurate diagnoses for cancer patients that the need for biopsies is significantly decreased.

-- Peptech Ltd. (ASX: PTD, AIM: PTDx)--A drug development company using peptides, focuses on cancer and inflammatory disease. The company receives royalty payments on Abbot's Humira(R) and Centocor's Remicade(R).

-- Progen Ltd. (ASX: PGL, NASDAQ: PGLA)--In just-released Phase 2a results, Progen's lead drug for liver cancer, PI-88, kept the disease at bay longer than standard treatment.

In addition to eG Capital, the New South Wales Department of State & Regional Development and O'Sullivan PLLC are hosts to the participating companies. Conference sponsors are: The American Australian Association, Australian Stock Exchange, Ernst & Young, Invest Australia, and The Trout Group LLC.

Biotech News

AZhttp, Inc.

Monday, April 16, 2007

Learn about latest health research and technology at Biomedical Engineering Day

Biotech News

Learn about latest health research and technology at Biomedical Engineering Day

TEMPE, Ariz. – It’s impossible to ignore the biotechnology buzz at Arizona State University. Arizona’s growing investment in the industry can be seen in the increasing number of biotech research facilities and projects at ASU’s main campus.

One of the most active areas in biotechnology is biomedical engineering, which is generating health and medical innovations such as new artificial hearts, limbs and eyes, and sophisticated health monitoring devices.

To increase public awareness about the rapidly emerging field, the student chapter of the Biomedical Engineering Society (BMES) will host Biomedical Engineering Day from 8 a.m. to 3:30 p.m. April 27. The annual event is a collaborative effort by BMES and the Harrington Department of Bioengineering in ASU’s Ira A. Fulton School of Engineering. It brings together bioengineering faculty, students and industry leaders to inform the community about achievements and opportunities in the field.

Because biomedical engineering involves experts in many disciplines, identifying who biomedical engineers are and describing what they do can get complicated. A National Institutes of Health (NIH) definition of biomedical engineering describes it as a field that integrates physical, mathematical and computational sciences and engineering principles to study biology, medicine, behavior and health.

“We want this event to be a public information session,” says Brian Onstot, co-president of ASU BMES. “The idea is to show a snapshot of biomedical engineering in a day to demonstrate who we are and what we do.”

BME Day will feature guest speakers from academia and industry, including Metin Akay, an international biomedical engineering leader and interim chair of the Harrington Department of Bioengineering, and Professor Andrew Laine, director of the Biomedical Imaging Center and vice-chair of Columbia University’s biomedical engineering department.

The event also will include a tour of some of the bioengineering research facilities on campus, including labs in the Interdisciplinary Science and Technology Building (ISTB 1) and the Schwada Classroom Office Building, including ASU’s new Bioengineering Design Studio. BME Day participants will have opportunities for hands-on experiences with biomedical engineering projects in physiology labs.

For more information about BME Day, and to register to attend, see the Harrington Department of Bioengineering web site at or e-mail

Registration for industry professionals and the public ends April 20.


Monday, April 09, 2007

Biotech Week In Review: Positive Territory For 2007 Seeking Alpha - New York,NY,USA Centient Biotech Investor submits: Biotech had a very positive wee

Biotech News

Biotech Week In Review: Positive Territory For 2007 Seeking Alpha - New York,NY,USA Centient Biotech Investor submits: Biotech had a very positive week. Over the four sessions, the Centient Biotech 200™ rose 116 points to 3995, a 3% climb. ...

DNA Sequencing
An explanation of how DNA sequencing works.

About Biotech / Biomedical: Most...

Companies form joint venture to market new biotech product By John Houston Business Journal, April 7, 2007 HOUSTON - Working together to solve a medical research challenge has led to the formation of a joint venture by a small biotech research operation based at The University of Texas Medical Branch ...

UTMB Newsroom

Biotech Companies
By Anonymous
What are the 5 best Biotech companies to work for? Are there any that still give options that will be worth something? I would be willing to take a risk if the payoff could be significant? Thanks for the serious replies.

Cafepharma Message Boards

Monday's Top Biotech & Medical Stocks
by HS Ayoub BioHealth Biotechnology NUVELO INC NEW [NUVO] +52.69% MEMORY PHARMACEUTICA [MEMY] +44.79% ANTIGENICS INC [AGEN] +42.72% CORCEPT THERAPEUTICS [CORT] +40.00% GENETIC TECH SPON [GENE] +33.27% Diagnostic. ...

BioHealth Investor

INC Research And GVK Partnership to make India Biotech Rich By RNCOS(RNCOS) Assessing the enormous growth potential of biotechnology in India, INC research organization has decided to tie-up with GVK biosciences to tap the growing market. On March 22, 2007, Triangle clinical research organization INC Research ...

HealthCare Industry Research

Biotech News

Pharma-biotech construction starts increase 5% to $4.3B Reliable Plant Magazine - Tulsa,OK,USA The pharmaceutical-biotech industry currently expects 135 capital and MRO
(maintenance) projects carrying a total investment value (TIV) of $4.3 billion to ...

Sector Snap: Biotech stocks hold steady
BusinessWeek - USA
Biotechnology stocks, weighed down by mixed movement by several bellwethers, remained flat Monday as the sector prepares for the unveiling of first-quarter ...

Young Indian Biotech Funding Woes
Red Herring - CA,USA
India ’s nascent biotech sector is facing a scarcity of risk capital during key early-stage funding, said a study published in Nature Biotechnology on ...

WMass biotech needs outlined
The Republican - Springfield,MA,USA
By MARCIA BLOMBERG. SPRINGFIELD - About 100 people urged legislators at a public hearing today to increase their support for biotechnology initiatives in ...

Biotech News
AZhttp, Inc.

Indian biotech firms set to grow-study

Biotech News

Indian biotech firms set to grow-study
Reuters AlertNet - London,England,UK
"At the moment we think of biotech in India as the baby elephant where information technology is the adult elephant," Singer told Reuters. ...

India’s biotech industry emerging as a world innovator Reliable Plant Magazine - Tulsa,OK,USA India ’s health biotech firms are emerging as a major global player, with growing means and know-how to produce innovative as well as generic drugs and ...

Biotech sector stays level on movement
BusinessWeek - USA
The mixed movement with some of the largest biotech drug developers equaled out to a nearly flat day, as the American Stock Exchange's biotechnology index ...

BIOTECH STOCKS Biotech, pharma finish mixed MarketWatch - USA By Val Brickates Kennedy, MarketWatch. BOSTON (MarketWatch) -- Benchmarks tracking biotechnology and pharmaceutical stocks closed mixed Monday, ...

AZhttp, Inc.